Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice.

@article{Kuroda2000HumanTN,
  title={Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice.},
  author={Kensei Kuroda and Keizo Miyata and Fumiko Fujita and Masako Koike and Masahide Fujita and M Nomura and S. Nakagawa and Yasuo Tsutsumi and T Kawagoe and Yachiyo Mitsuishi and Tadanori Mayumi},
  journal={Cancer letters},
  year={2000},
  volume={159 1},
  pages={
          33-41
        }
}
The antitumor effects of human tumor necrosis factor-alpha (TNF) mutant RGD-V29 (code no. F4614), that includes the cell adhesive sequence (4)Arg-(5)Gly-(6)Asp and (29)Arg-->Val substitution, were evaluated. The therapeutic index, a measure of the extent of the therapeutically-effective range, using three constitutive administrations of RGD-V29 in Meth A-bearing mice was 4.8, whereas that of recombinant human TNF (rhTNF) ((1)SSS(4)RTPSDK...(29)RR...(155)L) was 2.8, clearly indicating that the… Expand
A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
TLDR
The mutant rmhTNF exhibited an approximately 50-fold increase in cytotoxicity relative to the wild-type rhTNF on the mouse fibroblast cell line L929 in a standard cytot toxicity test, and at at least and at least 50 times higher LD50 as wild type rhT NF in mice. Expand
Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity
TLDR
A prokaryotic-expressed tumor necrosis factor-alpha mutant that exhibited a higher antitumor activity and a lower systemic toxicity compared with that of wild-type TNF-&agr; in both syngeneic murine tumor models and human tumor xenografts models satisfied clinical trial requirements, and was found to be safe at a dose of 4×106 IU/kg/day. Expand
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
TLDR
Data show that scFvMEL/TNF can target melanoma cells in vivo and can result in pronounced antimelanoma effects after systemic administration, and toxicology studies indicate the relative safety of this agent at doses that are therapeutically effective and provide guidance to projected phase I starting doses on patients at this schedule. Expand
Tumor therapeutics by design: targeting and activation of death receptors.
TLDR
Results generated with newly designed fusion proteins suggest that enhanced tumor-directed activity and prevention of undesirable actions of death receptors ligands is possible, thereby opening up a useful therapeutic window for all of the death receptor ligands, including CD95L. Expand
Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib
TLDR
It is suggested that therapy with TNF-α would be effective in some cases of non-small-cell lung cancer that have acquired resistance to gefitinib. Expand
Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma.
TLDR
Current progress in the understanding of TNF-alpha-mediated apoptosis for lung carcinoma is concentrated on and representative models of NF-kappaB-inhibiting gene therapy strategies are provided as examples of up-to-date approaches to defeat TNF resistance. Expand
Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy
TLDR
The outlook on apoptosis-inducing ligands as cancer treatments in diverse preclinical and clinical stages is reviewed and strategies of overcoming their natural limitations to improve their effectiveness are summarized. Expand
Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid
TLDR
The results indicate that the incorporation of NTA3-DTDA into liposomal drugs could represent a simple modification to the drug to allow engraftment of targeting molecules and to increase its efficacy. Expand
Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor.
TLDR
Evidence is provided to link both neutralization of endogenous growth factors and administration of exogenous bioactive cytokines as an integrative approach to cancer therapy and support the novel idea that the major inhibitory properties of proinflammatory cytokines on growth of breast cancer cells are manifested prominently in the presence of growth factors. Expand
Influence of rmhTNF on the chemotherapy treatment of small cell lung cancer
TLDR
The curative effectiveness of the rmhTNF combined with chemotherapy in the treatment of SCLC was more satisfactory than chemotherapy alone and the former could obviously improve the quality of life of the patients with SclC. Expand
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice
TLDR
V29 showed potent anti‐tumor activity in 3 consecutive injection schedules despite the decreases in toxicity compared with rhTNF, suggesting that V29 merits further investigation in pre‐clinical and clinical trials. Expand
Overcoming the metastasis-enhancing potential of human tumor necrosis factor alpha by introducing the cell-adhesive Arg-Gly-Asp sequence.
  • K. Miyata, Y. Mitsuishi, +4 authors M. Kato
  • Biology, Medicine
  • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 1995
TLDR
A mutein, F4168, of human tumor necrosis factor alpha containing the cell-adhesive Arg-Gly-Asp (RGD) sequence near the N terminus was constructed, indicating that the adhesive nature of the RGD sequence is conferred upon hTNF-alpha. Expand
A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: Implication for immunotherapy of human hepatocellular carcinoma
TLDR
Immunohistochemical analysis of the tumors treated by F4614 revealed that tumors were surrounded with a large number of Mac‐1+ cells and a small number of CD4+ and CD8+ T cells; that suggests that intratumoral injection of F 4614 elicited host immunoreactions, suggesting that F46 14 may be a new strategy for immunotherapy of HCC. Expand
Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma
TLDR
Data provide direct evidence for a functional role of TNF-R75, without ligand-dependent T NF-R55 involvement, in the induction of cytokine secretion in T cells. Expand
Selective species specificity of tumor necrosis factor for toxicity in the mouse.
TLDR
To mimic the two major phenomena caused by endotoxin administration, viz. lethality and antitumor effect, two distinct signals are needed in mice, and rmTNF can provide both, while rhTNF needs another agent (a sensitizer) to cause systemic toxicity. Expand
Novel Mutein of Tumor Necrosis Factor α (F4614) with Reduced Hypotensive Effect
TLDR
Results indicated that F4614 has several advantages as a systemic therapeutic drug in the treatment of cancer, and evidence that the Arg → Val mutation at position 29 is largely responsible for the reduced hypotensive effect is presented. Expand
Preferential Activity of Wild‐type and Mutant Tumor Necrosis Factor‐α against Tumor‐derived Endothelial‐like Cells
TLDR
Tumor‐derived endothelial‐like cells (tEC) are prepared by culturing human umbilical vein endothelial cells (HUVEC) in the presence of HT1080 human fibrosarcoma‐conditioned medium and acquire physiological properties of tumor‐associated vasculature, and may be a useful model system for the study of the mechanisms of TNF antitumor action. Expand
A novel Mutein of TNFα Containing the Arg-Gly-Asp Sequence Shows Reduced Toxicity in Intestine
TLDR
The results suggest that the Arg-Gly-Asp sequence introduced into the TNFα molecule abrogates the side effect of this cytokine such as tissue injury or shock, and that F4168 could be useful for systemic therapy. Expand
Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.
TLDR
Immunologic blot and immunoprecipitation analyses indicate that mAbs htr-9 and utr-1 recognize proteins of approximately 55 kDa and 75 kDa, respectively, which provide evidence for the existence of two distinct TNF receptor molecules that contribute to varying extent to the TNF binding by different human cells. Expand
Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice
The results of single‐agent chemotherapy, with 11 anti‐cancer agents, of 15 human gastro‐intestinal and breast cancer lines xenografted into nude mice indicate inherent individuality ofExpand
...
1
2
3
...